Michael Eccles
  • Department of Pathology, University of Otago, New Zealand
Research fields
  • Cancer biology
Personal information


Ph.D in Biochemistry, Department of Biochemistry, University of Otago, 1986

Current position

Professor and Chair in Cancer Pathology, Department of Pathology, University of Otago, Dunedin, New Zealand

Publications (since 2005)

  1. Eccles MR. PAX2 and Renal-Coloboma Syndrome in; Inborn Errors of Development 2nd edition (2008) C. Epstein, R. Erickson, A. Wynshaw-Boris (Eds). Oxford University Press, San Francisco.
  2. Eccles MR, Stayner, CK, Bockett, N. PAX2 and Renal-Coloboma syndrome in; The Kidney, From Normal Development to Congenital Abnormalities (2003), P.D. Vize, A.S. Woolf, J.B.L. Bard (Eds), Academic Press, London.
  3. Eccles MR. PAX2 and Renal-Coloboma Syndrome in; Inborn Errors of Development 1st edition (2004) C. Epstein, R. Erickson, A. Wynshaw-Boris (Eds). Oxford University Press, San Francisco.
  4. Ineson, J., Stayner, C., Hazlett, J., Slobbe, L., Robson, E., Legge, M. and Eccles, M. R. (2012). Somatic reactivation of expression of the silent maternal Mest allele and acquisition of normal reproductive behaviour in a colony of Peg1/Mest mutant mice. J Reprod Dev 58(4): 490-500.
  5. Burger, M. C., Brucker, D. P., Baumgarten, P., Ronellenfitsch, M. W., Wanka, C., Hasselblatt, M., Eccles, M. R., Klingebiel, T., Weller, M., Rieger, J., Mittelbronn, M. and Steinbach, J. P. (2012). PAX2 is an antiapoptotic molecule with deregulated expression in medulloblastoma. Int J Oncol 41(1): 235-241.
  6. Li CG, Eccles MR (2012). PAX genes in cancer; friends or foes? Frontiers in Genet: Canc Genet. 3, Jan 31, doi: 10.3389/fgene.2012.00006
  7. Yoon H-S, Eccles M, Mild Forms of Alport Syndrome; Hereditary Glomerulonephritis in the Absence of Extra-Renal Features (2011). In Glomerulonephritis, edited by S. Prabhakar. In-Tech Open Access Publishers, Croatia.
  8. Duncan, G., Stevens, G., Boberg, C., Harman, R., Eccles, M., Marshall, B., Potter, I., Rademaker, M. and MelNet Establishment, C. (2011). Melanoma Summit highlights best practice and priorities for action. N Z Med J 124(1334): 120-122.
  9. Bower M, Salomon R, Allanson J, Antignac C, Benedicenti F, Benetti E, Binenbaum G, Jensen UB, Cochat P, DeCramer S, Dixon J, Drouin R, Falk M, Feret H, Gise R, Hunter A, Johnson K, Kumar R, Lavocat MP, Martin L, Morinière V, Mowat D, Murer L, Nguyen H, Peretz-Ami G, Pierce E, Place E, Rodig N, Salerno A, Sastry S, Sato T, Sayer J, Schaafsma GCP, Shoemaker L, Stockton D, Tan W-H, Tenconi R, Vanhille P, Vats A, Wang X, Berta Warman B, Weleber RG, White SM, Wilson-Brackett C, Zand D, Eccles M, Schimmenti LA, Heidet L (2011). Update of PAX2 mutations in renal coloboma syndrome and establishment of a locus specific database. Human Mutation Dec 29 [Epub ahead of print].
  10. Eccles, M. (2011) Is Cancer the next of kin to the developing fetus? Australasian Science. December, 32-33.
  11. Li, C. G., Nyman, J. E., Braithwaite, A. W. and Eccles, M. R. (2011). PAX8 promotes tumor cell growth by transcriptionally regulating E2F1 and stabilizing RB protein. Oncogene 30(48): 4824-4834.
  12. Bower, M., Eccles, M., Heidet, L. and Schimmenti, L. A. (2011). Clinical utility gene card for: renal coloboma (Papillorenal) syndrome. Eur J Hum Genet 19(9). [Epub ahead of print].
  13. Otto, E. A., Ramaswami, G., Janssen, S., Chaki, M., Allen, S. J., Zhou, W., Airik, R., Hurd, T. W., Ghosh, A. K. and Wolf, M. T. (2010). Mutation analysis of 18 nephronophthisis associated ciliopathy disease genes using a DNA pooling and next generation sequencing strategy. Journal of medical genetics: jmg. 2010.082552
  14. He, S., Li, C. G., Slobbe, L., Glover, A., Marshall, E., Baguley, B. C. and Eccles, M. R. (2011). PAX3 knockdown in metastatic melanoma cell lines does not reduce MITF expression. Melanoma research 21(1): 24-34. [Epub ahead of print].
  15. He, S., Yoon, H. S., Suh, B. J. and Eccles, M. R. (2010). PAX3 Is extensively expressed in benign and malignant tissues of the melanocytic lineage in humans. J Invest Dermatol 130(5): 1465-1468. (IF=5.251).
  16. Jeffs, A. R., Glover, A. C., Slobbe, L. J., Wang, L., He, S., Hazlett, J. A., Awasthi, A., Woolley, A. G., Marshall, E. S., Joseph, W. R., Print, C. G., Baguley, B. C. and Eccles, M. R. (2009). A gene expression signature of invasive potential in metastatic melanoma cells. PLoS One 4(12): e8461.
  17. Monnich, M., Banks, S., Eccles, M., Dickinson, E. and Horsfield, J. (2009). Expression of cohesin and condensin genes during zebrafish development supports a non-proliferative role for cohesin. Gene Expr Patterns 9(8): 586-594. (IF=2.112).
  18. Hueber, P. A., Fukuzawa, R., Elkares, R., Chu, L., Blumentkrantz, M., He, S. J., Anaka, M. R., Reeve, A. E., Eccles, M., Jabado, N., Iglesias, D. M. and Goodyer, P. R. (2009). PAX3 is expressed in the stromal compartment of the developing kidney and in Wilms tumors with myogenic phenotype. Pediatr Dev Pathol 12(5): 347-354. (IF=1.087).
  19. Frost, V., Grocott, T., Eccles, M. R. and Chantry, A. (2008). Self-regulated Pax gene expression and modulation by the TGFbeta superfamily. Crit Rev Biochem Mol Biol 43(6): 371-391.(IF=8.306).
  20. Chen, Y. J., Campbell, H. G., Wiles, A. K., Eccles, M. R., Reddel, R. R., Braithwaite, A. W. and Royds, J. A. (2008). PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma. Cancer Res 68(14): 5724-5732. (IF=7.672).
  21. Hueber, P. A., Iglesias, D., Chu, L. L., Eccles, M. and Goodyer, P. (2008). In vivo validation of PAX2 as a target for renal cancer therapy. Cancer Lett 265(1): 148-155. (IF=3.504).
  22. Schimmenti L and Eccles M (June 2007) Renal Coloboma Syndrome in: GeneReviews at GeneTests: Medical Genetics Information Resource [database online]. Copyright, University of Washington, Seattle, 1997-2007. Available at http://www.genetests.org.
  23. Lu, W., van Eerde, A. M., Fan, X., Quintero-Rivera, F., Kulkarni, S., Ferguson, H., Kim, H. G., Fan, Y., Xi, Q., Li, Q. G., Sanlaville, D., Andrews, W., Sundaresan, V., Bi, W., Yan, J., Giltay, J. C., Wijmenga, C., de Jong, T. P., Feather, S. A., Woolf, A. S., Rao, Y., Lupski, J. R., Eccles, M. R., Quade, B. J., Gusella, J. F., Morton, C. C. and Maas, R. L. (2007). Disruption of ROBO2 is associated with urinary tract anomalies and confers risk of vesicoureteral reflux. Am J Hum Genet 80(4): 616-632. (IF=11.982).
  24. Wilson, J. C., Yoon, H. S., Walker, R. J. and Eccles, M. R. (2007). A novel Cys1638Tyr NC1 domain substitution in alpha5(IV) collagen causes Alport syndrome with late onset renal failure without hearing loss or eye abnormalities. Nephrol Dial Transplant 22(5): 1338-1346. (IF=3.167)
  25. Stayner, C., Iglesias, D. M., Goodyer, P. R., Ellis, L., Germino, G., Zhou, J. and Eccles, M. R. (2006). Pax2 gene dosage influences cystogenesis in autosomal dominant polycystic kidney disease. Hum Mol Genet 15(24): 3520-3528. (IF=7.764).
  26. Dziarmaga, A., Hueber, P. A., Iglesias, D., Hache, N., Jeffs, A., Gendron, N., Mackenzie, A., Eccles, M. and Goodyer, P. (2006). Neuronal apoptosis inhibitory protein is expressed in developing kidney and is regulated by PAX2. Am J Physiol Renal Physiol 291(4): F913-920. (IF=4.263).
  27. Dziarmaga, A., Eccles, M. and Goodyer, P. (2006). Suppression of ureteric bud apoptosis rescues nephron endowment and adult renal function in Pax2 mutant mice. J Am Soc Nephrol 17(6): 1568-1575. (IF=7.24).
  28. Robson, E. J., He, S. J. and Eccles, M. R. (2006). A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6(1): 52-62. (IF=31.694).
  29. Hueber, P. A., Waters, P., Clark, P., Eccles, M. and Goodyer, P. (2006). PAX2 inactivation enhances cisplatin-induced apoptosis in renal carcinoma cells. Kidney Int 69(7): 1139-1145. (IF=4.927).
  30. Utsch, B., Sayer, J. A., Attanasio, M., Pereira, R. R., Eccles, M., Hennies, H. C., Otto, E. A. and Hildebrandt, F. (2006). Identification of the first AHI1 gene mutations in nephronophthisis-associated Joubert syndrome. Pediatr Nephrol 21(1): 32-35. (IF=1.44).
  31. Torban, E., Dziarmaga, A., Iglesias, D., Chu, L. L., Vassilieva, T., Little, M., Eccles, M., Discenza, M., Pelletier, J. and Goodyer, P. (2006). PAX2 activates WNT4 expression during mammalian kidney development. J Biol Chem 281(18): 12705-12712. (IF=6.355).
  32. Johnstone, A. C., Davidson, B. I., Roe, A. R., Eccles, M. R. and Jolly, R. D. (2005). Congenital polycystic kidney disease in lambs. N Z Vet J 53(5): 307-314. (IF=1.118).
  33. He, S. J., Stevens, G., Braithwaite, A. W. and Eccles, M. R. (2005). Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther 4(6): 996-1003.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.